Vor leads a new pack of IPOs to price, con­tin­u­ing steady stream of com­pa­nies mak­ing leap to the Nas­daq

Six of the 10 biotechs that were ex­pect­ed to price their IPOs this week have now of­fi­cial­ly made the jump on­to the Nas­daq, con­tin­u­ing a record pace dat­ing back to 2020.

Vor Bio­phar­ma, Sid­dhartha Mukher­jee’s cell ther­a­py start­up, of­fi­cial­ly priced its 9,828,017 shares of com­mon stock Fri­day at $18 per share, rais­ing $176.9 mil­lion. Vor’s IPO, trad­ing un­der the tick­er $VOR, will close Feb. 9, with Gold­man Sachs, Ever­core ISI, Bar­clays and Stifel op­er­at­ing as bookrun­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER